Clinical Lung Cancer · Oct 23, 2026
De Novo Lung Cancer after Lung Transplantation: Rethinking Surveillance and Early Detection
By Mehdizadeh-Shrifi A, Lennartz F, Merhej H et al.
PURPOSE: While lung transplantation (LTx) is an established therapy for end-stage lung disease in an aging population, lung cancer (LC) complicates the transplant journey. This study aimed to elucidate factors associated with LC development and post-diagnosis mortality. PATIENTS AND METHODS: We performed a retrospective single-center observational study at a certified lung cancer center of patients with primary LC after LTx between 1997 and 2025. Characteristics, survival and predictors of development of LC and mortality were assessed. RESULTS: Of 2,541 LTx recipients, 47 developed LC, corresponding to an incidence of 1.9%. The median time from LTx to LC diagnosis was 6.05 [3.44-8.89] years. Age at transplantation was 55 [IQR 45-59] years; donor age was 52 [46-60] years. Most tumors arose in the transplanted lung (N = 33, 70%). Survival following LC diagnosis was 0.57 [0.22-1.64] years. Unilateral LTx (HR 2.89), donor smoking history (HR 1.82), ILD/pulmonary fibrosis (HR 1.49), older recipient age (HR 1.37 per 10 years), and cumulative recipient smoking exposure (HR 1.13 per 10 pack-years) were associated with LC development. Stage-IV disease (HR 2.56), unilateral LTx (HR 2.13), prolonged time to LC diagnosis (HR 2.09), and advanced donor age (HR 2.03) were associated with mortality. CONCLUSION: Lung cancer after LTx is a rare complication with poor prognosis. Recipient-, donor, and transplant-related characteristics were associated with LC development, while advanced-stage disease and selected transplant-related factors were associated with mortality. Screening protocols should be intensified in an aging LTx population.
doi.org/10.1016/j.cllc.2026.10.008Open accessPubMed 43025052Populations